Lab Industry Buzz: The 10 Biggest DX Mergers of 2019

Publication Date: Feb 1, 2020

Conspicuous by its absence from the list is the proposed $1.2 billion Illumina takeover of Pacific Biosciences which suddenly seems to be in major trouble. (See DX Deals on page 1 for the details.) Here are the 10-highest value M&A diagnostics deals that did come off in 2019.

Top 10 Lab M&A Deals of 2019

Rank	Buyer	Target	Reported Price
1	Danaher	GE Biopharma	$21.4 billion
2	Exact Sciences	Genomic Health	$2.8 billion (cash + stock)
3	Thermo Fisher Scientific	Brammer Bio	$1.7 billion
4	Agilent Technologies	BioTek Instruments	$1.17 billion
5	PHC Holdings (formerly known as Panasonic Healthcare Holdings)	Thermo Fisher Scientific	$1.14 billion
6	Sartorius	Danaher	$750 million*
7	Covance Drug Development (part of LabCorp)	Envigo	$485 million
8	Beckman Coulter Life Sciences	Labcyte	$308 million
9	PerkinElmer	Cisbio Bioassays	$219.8 million
10	Clayton, Dubilier & Rice investment funds	Cynosure (owned by Hologic)	$205 million

* Announced in 2019 with closing scheduled for 2020

**************

This article originally appeared in G2 Intelligence, Laboratory Industry Report, January 2020

My Role
Membership
Learning
Get Involved
Careers
About ASCP
Board of Certification
News

Chicago (Headquarters)

33 West Monroe Street, Suite 1600, Chicago, IL 60603

Privacy Policy

Terms of Use